It is well established that young women with breast cancer have higher rates of aggressive tumor features, such as larger tumors, higher tumor grade, lymph node involvement, hormone receptor negativity, HER2 receptor positivity, higher Ki67 expression and more aggressive molecular subtypes such as triple negative and HER2 positive7. This evidence concerns the gene ERBB2 and neoplasm.